key: cord-0725400-km8m1mgk
authors: Syed, Fahim; Li, Wei; Relich, Ryan F; Russell, Patrick M; Zhang, Shanxiang; Zimmerman, Michelle K; Yu, Qigui
title: Excessive matrix metalloproteinase-1 and hyperactivation of endothelial cells occurred in COVID-19 patients and were associated with the severity of COVID-19
date: 2021-04-22
journal: J Infect Dis
DOI: 10.1093/infdis/jiab167
sha: 406f09c7c894c8940c498a4a1a16f3faee0a255c
doc_id: 725400
cord_uid: km8m1mgk

Systemic vascular injury occurs in COVID-19 patients, yet the underlying mechanisms remain unknown. To clarify the role of inflammatory factors in COVID-19 vascular injury, we used a multiplex immunoassay to profile 65 inflammatory cytokines/chemokines/growth factors in plasma samples from 24 hospitalized (severe/critical) COVID-19 patients, 14 mild/moderate cases, and 13 healthy controls (HCs). COVID-19 patients had significantly higher plasma levels of 20 analytes than HCs. Surprisingly, only one cytokine (MIF) was among these altered analytes, while the rest were chemokines/growth factors. Additionally, only MMP-1 and VEGF-A were significantly elevated in hospitalized COVID-19 patients when compared to mild/moderate cases. We further studied MMP-1 enzymatic activity and multiple endothelial cell (EC) activation markers (soluble forms of CD146, ICAM-1, and VCAM-1) and found that they were highly dysregulated in COVID-19 patients. Thus, COVID-19 patients have a unique inflammatory profile, and excessive MMP-1 and hyperactivation of ECs are associated with the severity of COVID-19.

Coronavirus disease 2019 (COVID- 19) , an infectious disease caused by a novel coronavirus (severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2), has created an unprecedented global health and economic crisis. By the end of 2020, confirmed COVID-19 cases surpassed 84 million globally, resulting in over 1.8 million deaths. COVID-19 patients can experience various clinical manifestations, including asymptomatic, mild, moderate, severe, or critical symptoms. Growing evidence shows that COVID-19 is a vascular illness, not solely a respiratory disease. Histopathological examinations of post-mortem tissues of COVID-19 patients have revealed (1) diffuse alveolar damage with perivascular infiltration of inflammatory cells [1] , (2) extensive damage to the lining of blood vessels throughout the body [1] [2] [3] , (3) severe endothelial injury and widespread thrombosis in the lungs, heart, liver, kidney, and small intestine [1] [2] [3] , (4) viral particles in endothelial cells (ECs) of the glomerular capillary loops [2] , and (5) caspase-3-positive apoptotic ECs in the lung and intestine tissues [2] . In addition, a recent study has shown that COVID-19 patients in intensive care units (ICUs) have higher counts of circulating ECs (CECs) than non-ICU patients [4] . CECs are stressed cells detached from injured blood vessels, thereby indicating severe vascular injury [5] . Collectively, patients with severe COVID-19 exhibit impaired endothelial and microcirculatory functions across vascular beds of different organs, which may be particularly relevant for vulnerable individuals with pre-existing endothelial dysfunctions such as diabetes, hypertension, and cardiovascular diseases, all of which are associated with adverse outcomes in COVID-19 [2, 6, 7] .

The pathological mechanisms underlying vascular injury in COVID-19 remain unclear, although cytokine storm syndrome (CSS) and SARS-CoV-2 infection are considered contributors. SARS-CoV-2 is a member of the family Coronaviridae, genus Betacoronavirus, and is closely related to the SARS-CoV that caused the 2003 SARS pandemic [8] [9] [10] . CSS plays a critical role in the pathogenesis of SARS-CoV infection and represents a major cause of morbidity in SARS patients [11] . Elevated circulating concentrations of numerous A c c e p t e d M a n u s c r i p t 5 inflammatory factors such as IL-6, IFN-γ, IL-8, and IP-10 have been reported in SARS patients when compared to healthy controls (HCs) [12, 13] . Circulating IL-6 levels are also elevated in COVID-19 patients and are cited as evidence of COVID-19 CSS [14, 15] .

However, the levels of IL-6 and other inflammatory cytokines such as IL-8 are significantly less elevated in COVID-19 patients than the values typically reported in patients with CSS caused by conditions such as septic shock [16] . Indeed, the concentrations of IL-6, IL-8, and TNF-α, three of the most important inflammatory mediators in human diseases with CSS [17] , in COVID-19 patients are similar to those found in ICU patients with cardiac arrest or trauma, conditions that are not notable for cytokine storms [16] . These findings bring into question whether a cytokine storm occurs in COVID-19, and whether IL-6, IL-8, and TNF-α act as key inflammatory mediators for fatal manifestations in patients with severe COVID-19 [17] . Our results echo recent NIH guidelines that note there are insufficient data to recommend IL-6 inhibitors for the treatment of COVID-19 [18] . In fact, efforts to combat cytokine storm in patients with severe COVID-19 have proven unsuccessful [19] .

SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a primary receptor for viral binding and entry [20, 21] . Viral entry is also facilitated by transmembrane protease serine 2 (TMPRSS2) and neuropilin-1 (NRP1) [20, 22] . ACE2, TMPRSS2, and NRP1 are highly abundant on the lung alveolar type II epithelial (AT2) cells, rendering AT2 cells highly susceptible to productive SARS-CoV-2 infection [22] [23] [24] [25] . ACE2, TMPRSS2, and NRP1 are also expressed on the surface of ECs [22, 23] , albeit at lower levels than in AT2 cells [22] , suggesting that these molecules may facilitate SARS-CoV-2 infection of ECs. Indeed, SARS-CoV-2 particles were observed in ECs in kidney tissues from COVID-19 patients 8 , yet the underlying mechanisms are unclear.

To explore the profile and key players of the cytokine storm in COVID-19, we used a multiplex immunoassay to simultaneously measure 65 inflammatory cytokines/chemokines/growth factors in plasma samples from hospitalized (severe/critical) COVID-19 patients, mild/moderate cases, and HCs. Surprisingly, matrix metalloproteinase-1 A c c e p t e d M a n u s c r i p t 6 (MMP-1) and vascular endothelial growth factor A (VEGF-A), not conventional inflammatory cytokines such as IL-6, were two of the most unambiguously elevated inflammatory factors in hospitalized COVID-19 patients when compared to mild/moderate cases or HCs.

Spearman correlation analysis revealed that the plasma levels of MMP-1 and VEGF-A in hospitalized COVID-19 patients were positively correlated. Given that excessive MMP-1 plays a central role in tissue destruction in a wide variety of vascular diseases and that elevated VEGF-A, an EC activation markers, increases vascular permeability [26] , we further 

This study was performed with the approval of the Institutional Review Boards at Indiana University School of Medicine. Blood samples were drawn after each participant provided a written informed consent form.

The study subjects included 24 hospitalized COVID-19 patients, 14 mild/moderate cases, and 13 HCs. Hospitalized COVID-19 patients included SARS-CoV-2-infected individuals who developed severe illness (dyspnea, hypoxia, >50% lung involvement on imaging, or required oxygen support [27] ) or critical disease with complications such as respiratory failure, thrombosis, and/or multi-organ failure [27] . Some of these hospitalized patients were admitted to ICUs. Patients with mild/moderate COVID-19 were characterized with mild respiratory symptoms (nasal congestion, runny nose, and a sore throat) or mild A c c e p t e d M a n u s c r i p t 7 pneumonia [27] . All COVID-19 patients were treated in Indiana University (IU) Health hospitals in Indianapolis, Indiana, during May -December 2020. Plasma samples from HCs were selected from our banked blood samples that were collected before the COVID-19 pandemic as described in our previous reports [28, 29] . Demographics of HCs were matched with COVID-19 patients so that there were no significant differences between age or gender of HCs and COVID-19 subjects. The demographic and clinical characteristics of COVID-19 patients and HC demographics were summarized in Table 1 . 

Statistical analysis was performed using GraphPad Prism 6.0 (La Jolla, CA). Data were expressed as mean ± standard error of the mean (SEM). Differences between two groups were calculated using the Mann Whitney test. Kruskal-Wallis test with Dunn's corrections was used for comparisons among three groups. Chi-square test was used for comparison between groups for categorical variables. The linear relationship between two variables was analyzed using the Spearman correlation test. P <0.05 was considered statistically significant.

A c c e p t e d M a n u s c r i p t 9

The study subjects included 24 hospitalized patients with severe/critical COVID- 19, 14 patients with mild/moderate COVID-19, and 13 HCs. Severe/critical COVID-19 patients were hospitalized in Indiana University (IU) Health hospitals in Indianapolis, Indiana and mild/moderate COVID-19 patients visited IU Health hospitals between May -December 2020. HCs were recruited before the COVID-19 pandemic as described in our previous report [29] . The demographics and clinical characteristics of these subjects were summarized in Table 1 . There were no differences in age, gender, or race distributions between these three groups. Hospitalized COVID-19 patients had lower absolute lymphocyte count (ALC) and higher levels of D-dimer, C-reactive protein (CRP), and ferritin than patients with mild/moderate COVID-19 (Table 1 ). There were no differences in white blood cell (WBC) or neutrophil counts between the hospitalized patients and patients with mild/moderate COVID-19 ( Table 1) .

The pathogenesis of severe or critical COVID-19 is complex and has been suggested to include a cytokine storm that sustains an aberrant systemic immune response [30] . To elucidate the profile and key pathogenic inflammatory mediators of the cytokine storm in COVID-19 patients, we used a multiplex immunoassay to simultaneously detect plasma levels of 65 cytokines/chemokines/growth factors in hospitalized (severe/critical) patients, mild/moderate cases, and HCs. In comparison to HCs, COVID-19 patients had significantly higher plasma levels of 20 of these analytes ( Table 2) . Among these altered analytes, (Table 2) . Surprisingly, MMP-1 and VEGF-A were the only two elevated inflammatory factors that were significantly higher in hospitalized COVID-19 patients when compared to mild/moderate cases (Table 2 and Figure   1A ), while all others did not show differences between hospitalized and mild/moderate COVID-19 patients (Table 2) . Spearman correlation analysis revealed that the plasma levels MCP-1, MCP-2, IL-6, and IL-18 were the 4 analytes that were significantly increased in hospitalized patients, but not in mild/moderate cases, when compared to HCs (Table 2 and Figure 1A ). However, plasma levels of IL-6 and IL-18 were elevated in some, but not all, patients with severe/critical COVID-19. As shown in Figure 1A , IL-6 was detected in 0 HCs (Table 2) .

Twenty-three analytes, primarily inflammatory cytokines such as IL-8 and TNF-α, were below the limit of detection in the majority of hospitalized cases, mild/moderate cases, and HCs (Table 2) . (Table 2) . Their plasma levels were positively correlated (Figure 1) , suggesting that there are interactions between MMPs and ECs in COVID-19. We further studied plasma MMP-1 enzymatic activity and the EC activation marker profiles. To date, only one MMP, MMP-9, has been analyzed in one pilot COVID-19 study [31] . This study measured plasma MMP-9 levels using an enzyme immunoassay, and showed that hospitalized COVID-19 patients had higher MMP-9 levels than HCs [31] .

However, no MMP has had their enzymatic activity studied in COVID-19 patients. We found that the enzymatic activity of MMP-1 was significantly increased in hospitalized COVID-19

patients when compared to HCs and those with mild/moderate COVID-19 ( Figure 2A) . Thus, both the levels and the enzymatic activity of MMP-1 were up-regulated in the peripheral blood of COVID-19 patients, particularly in patients with severe/critical COVID-19.

We also found that hospitalized COVID-19 patients had significantly higher plasma levels of sCD146, sICAM-1, and sVCAM-1, than HCs. Mild/moderate COVID-19 patients also had higher levels of sCD146, but neither sICAM-1 nor sVCAM-1, than HCs ( Figure 2B ).

There were no differences in the plasma levels of sCD146, sICAM-1, or sVCAM-1 between hospitalized and mild/moderate COVID-19 patients ( Figure 2B ). As I-FABP is solely expressed in epithelial cells of the mucosal layer of the small intestine and used as a plasma marker of intestinal epithelial injury [32] , an I-FABP ELISA assay was also performed to study and compare the effects of COVID-19 on epithelial cells versus ECs. In contrast to EC activation markers, plasma I-FABP levels were not different between hospitalized COVID-19 patients, mild/moderate cases, and HCs ( Figure 2C 

We analyzed the relationship between demographic factors (age, gender, and race) and circulating MMP-1 and EC activation markers in hospitalized COVID-19 patients.

Twenty-four hospitalized COVID-19 patients were split into 2 age groups: 10 cases ≤ 55 years old and 14 cases > 55 years old. As shown in Figure 3A , plasma VEGF-A levels were significantly higher in hospitalized COVID-19 patients >55 years old when compared to cases ≤ 50 years old. Plasma levels of MMP-1, sICAM-1, sVCAM-1, and active MMP-1 trended higher in the older group ( Figure 3A) . We also found that plasma sVCAM-1 levels were significantly higher in males (n=10) when compared to females (n=14) ( Figure 3B ).

There were no differences in the plasma levels of MMP-1, active MMP-1, or EC activation markers in African-Americans (n=10) when compared to Caucasian Americans (n=13) ( Figure 3C ). M a n u s c r i p t shock [16] .

The vast majority of altered circulating inflammatory factors in COVID-19 patients were chemokines, growth factors, and soluble receptors, not inflammatory cytokines. Our results indicate that COVID-19 patients have inflammatory profiles that are distinct from the cytokine storms found in other human diseases [30, 33] , and also question whether a cytokine storm occurs in COVID-19. The term "cytokine storm" was first coined to describe the excessive release of inflammatory cytokines by immune cells in graft-versus-host disease (GVHD) [30, 33] . Since then, CSS has been reported in a wide range of human diseases including cancer patients undergoing chimeric antigen receptor (CAR) T cell therapy [34] , sepsis [35] , and viral infections [13, 36] . Indeed, CSS is a common complication of viral respiratory infections such as infection with SARS-CoV [13, 37, 38] , and the Middle East respiratory syndrome coronavirus (MERS-CoV) [39] . In these CSS-linked diseases, IL-6, IFN-γ, IL-1β, and TNF-α are highly elevated and act as hallmarks. In HCs, mean levels of circulating IL-6 have been reported to be <5 pg/m [40] , which can be increased to >10,000 A c c e p t e d M a n u s c r i p t 14 pg/mL in cancer patients on CAR T cell therapy [41] . The substantial elevation of IL-6 and its correlation with disease severity have resulted in IL-6 inhibitors such as sarilumab, siltuximab, and tocilizumab becoming therapeutic agents that can effectively treat CSSassociated diseases [41] . Circulating IL-6 levels are also elevated in COVID-19 patients and cited as evidence of COVID-19 CSS [14, 15] . However, as previously reported, elevated IL-6 levels in COVID-19 patients are minuscule compared to those found in individuals on CAR T cell therapy and other CSS-associated diseases [17, 42] , suggesting that IL-6 does not act as a key inflammatory mediator for fatal manifestations in patients with severe or critical COVID-19 [17] . Thus, IL-6 inhibitors are not recommended to be used as therapeutic agents to treat COVID-19 as noted by NIH guidelines [18] . Our results provide evidence that explains why efforts to combat cytokine storm have proven unsuccessful in severe COVID- types I, II, and III, and plays a critical role in vascular remodeling and vascular diseases [46] .

In addition, MMP-1 acts as a potent agonist for protease-activated receptor-1 (PAR1) [47] , a A c c e p t e d M a n u s c r i p t 15 G protein-coupled protease-activated receptor, on the surface of a variety of cell types such as ECs [47] . MMP-1/PAR1 signaling can increase expression of VEGF receptor-2 (VEGFR2) [48] , the main receptor for VEGF, on ECs to trigger EC activation. We found that the levels of MMP-1, VEGF-A, and MMP-1 enzymatic activity were significantly elevated in the peripheral blood in hospitalized (severe/critical) COVID-19 patients compared to mild/moderate cases or HCs, suggesting that MMP-1/PAR1/VEGFR2/VEGF-A signaling may be in a hyperactivation state in ECs in COVID-19 patients.

In addition to VEGF-A, other EC activation markers including sCD146, sICAM-1, and sVCAM-1, but not epithelial cell activation marker I-FABP, were highly elevated in COVID- 19 . These findings indicate that systemic ECs, not epithelial cells, are significantly affected by COVID-19.

Age is a well-known factor that influences the severity and fatality of COVID-19 [49] .

The risk for severe illness with COVID-19 increases with age, with older adults at highest risk [49] . Other demographic factors such as gender and race have also been linked with risk for the severity of COVID-19. We found that excessive MMPs and/or circulating markers of EC activation increased with age or were higher in hospitalized male COVID-19 patients, but were not affected by race. However, we realize that our sample size of hospitalized COVID-19 patients, after splitting into 2 demographic groups, is too small to make significant statistical differences.

Additional limitations of our study include the lack of COVID-19-negative hospitalized patients, which might have allowed us to identify a unique profile of inflammatory mediators in hospitalized COVID-19 patients [50] . We were unable to detect IL-8 and TNF-α, 2 factors shown to be elevated by multiplex and ELISA immunoassays in critically ill COVID-19 patients with sepsis [50] . This discrepancy is likely due to differences in COVID-19 patient populations, clinical parameters, and detection limits of the different multiplex immunoassay kits used. 

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Endothelial cell infection and endotheliitis in COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19

Circulating endothelial cells. Biomarker of vascular disease

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and metaregression

Could a family history of type 2 diabetes be a risk factor to the endothelial damage in the patient with COVID-19? Med Hypotheses

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus

Cytokine release syndrome in severe COVID-19

An interferon-gamma-related cytokine storm in SARS patients

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions

Rethinking interleukin-6 blockade for treatment of COVID-19

Interleukin-6 Inhibitors. COVID-19 Treatment Guidelines

Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study

Alcohol Abstinence Does Not Fully Reverse Abnormalities of Mucosal-Associated Invariant T Cells in the Blood of Patients With Alcoholic Hepatitis

Into the eye of the cytokine storm

Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure

The intestinal fatty acid-binding protein as a marker for intestinal damage in gastroschisis

Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens

Toxicity management for patients receiving novel Tcell engaging therapies

Role of cytokines as a double-edged sword in sepsis

New fronts emerge in the influenza cytokine storm

Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome

Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS

Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection

Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays

Current status of chimeric antigen receptor therapy for haematological malignancies

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

COVID-19-Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?

Chemokines and chemokine receptors during COVID-19 infection

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease

Matrix metalloproteases and PAR1 activation

Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells

The coronavirus is most deadly if you are older and male -new data reveal the risks

Inflammation Profiling of Critically Ill Coronavirus Disease

Values of D-Dimer, CRP, ferritin, WBC, ANC, and ALC in HCs are the reference numbers for healthy population. *p<0.05, ***p<0.001 (increased), & #p<0.05 (decreased): comparison between mild/moderate or hospitalized COVID-19 and HCs. WBC, white blood cell count

ANC, absolute neutrophil count

ALC, absolute lymphocyte count

HC, healthy control; Mild, patients with mild/moderate COVID-19

Note: Data are expressed as median and interquartile range. HC, healthy control; Mild, patients with mild/moderate COVID-19

Kruskal-Wallis test with Dunn's corrections was used for comparisons among three groups of HCs, mild/severe cases, and hospitalized COVID-19 patients. *p <0.05, **p <0.01, or ***p <0.001 for comparison between hospitalized COVID-19 and HCs, #p <0.05 for comparison between hospitalized COVID-19 patients and mild/moderate cases

Sixty-five human cytokines/chemokines/growth factors include 33 cytokines

MIP-1β, MIP-3α, and SDF-1α), 6 growth factors/regulators (FGF-2, HGF, MMP-1, NGF-β, SCF, VEGF-A), and 8 soluble receptors

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 23 A c c e p t e d M a n u s c r i p t 25 Table 2 

A c c e p t e d M a n u s c r i p t